Core Viewpoint - The company has developed an action plan titled "Enhancing Quality, Increasing Efficiency, and Returning to Shareholders" to improve operational quality and governance in response to regulatory requirements and its own strategic goals [1][8]. Group 1: Business Focus and Quality Improvement - The company is a state-controlled comprehensive pharmaceutical enterprise engaged in the research, production, and sales of pharmaceutical and biological manufacturing products, with a mission to develop ecological medicine and serve human health [1]. - Future strategies include optimizing business structure and enhancing operational efficiency, focusing on product innovation and establishing a high-quality development system [2]. Group 2: Innovation and Product Line Expansion - The company adheres to an "innovation-driven development" strategy, maintaining R&D investment at over 6% of revenue during the 14th Five-Year Plan period, and has achieved breakthroughs in innovative drugs and biological manufacturing [2][3]. - The product structure is continuously optimized, with competitive advantages in anti-infection, diabetes, and cardiovascular drugs, and a growing pipeline of specialty products [2]. Group 3: Governance and Compliance - The company is committed to improving its governance structure in accordance with relevant laws and regulations, ensuring transparency and effective checks and balances [3][4]. - It has revised its articles of association and internal control systems to enhance operational standardization and compliance [3]. Group 4: Long-term Return Mechanism - The company emphasizes investor returns, with cash dividends exceeding 30% of net profit attributable to ordinary shareholders from 2021 to 2024, and has incorporated a cash dividend policy into its articles of association [5]. - The company aims to enhance its operational quality to increase investment value and fulfill its commitment to shareholder returns [5]. Group 5: Information Disclosure and Investor Relations - The company adheres to strict information disclosure regulations, focusing on transparency and the quality of disclosed information to ensure all shareholders receive timely updates [6]. - It plans to enhance investor relations management through diversified communication channels and actively seek investor feedback [6]. Group 6: Management of Key Personnel - The company prioritizes the responsibilities of key stakeholders, including controlling shareholders and senior management, to safeguard the interests of minority shareholders [7]. - It implements a multi-level governance system to ensure compliance and risk management, while enhancing the performance evaluation and incentive mechanisms for senior management [7].

Core Viewpoint - The company, LuKang Pharmaceutical, has announced a special action plan titled "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" aimed at enhancing operational quality and driving innovation in product development [1] Group 1: Action Plan Details - Focus on core business to improve operational quality [1] - Drive development through innovation and continuously enrich the product line [1] - Optimize corporate governance to enhance operational standards [1] - Establish a long-term return mechanism to share development results [1] - Improve the quality of information disclosure and strengthen investor relations management [1] - Strengthen management of key personnel to solidify responsibility [1] - Additional explanations provided [1]

证券代码:600789 证券简称:鲁抗医药 公告编号:2026-006 山东鲁抗医药股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为贯彻落实国务院《关于进一步提高上市公司质量的意见》，积极响应上海 证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》等相关要 求，山东鲁抗医药股份有限公司（以下简称"公司"）结合自身发展战略和实际 经营情况，制定"提质增效重回报"行动方案。具体方案如下： 一、聚焦主营业务，提升经营质量 公司属于国有控股综合性医药企业，主要从事医药及生物制造产品的研发、 生产和销售等业务，产品涉及医药制剂、原料药、中成药、动植物保健、合成生 物等领域。公司以发展生态医药、服务人类健康为使命，制造优质安全高效的药 品，服务人民医疗健康事业。 未来，公司将立足生物医药及生物制造主业，聚焦业务结构优化与经营质效 提升，系统构建高质量发展体系。在产品创新方面，公司将落实研发"精品工程" 的整体要求，以丰富产品管线为基础，以充实产线负荷为依托，强化"两优势、 ...

Core Insights - LuKang Pharmaceutical (600789) is actively advancing automation, digitalization, and intelligence in its operations, significantly enhancing equipment automation and intelligence levels, and accelerating high-end and intelligent development [1] Group 1: Automation and Digitalization Initiatives - The company has optimized resource allocation and management capabilities, establishing smart factories and intelligent enterprises to enhance core competitiveness and achieve significant growth [1] - By 2025, LuKang Pharmaceutical aims to be recognized as an excellent intelligent factory by the Ministry of Industry and Information Technology, and has completed the construction of two digital pilot workshops, SY25 and SS16, which have increased production capacity and labor productivity [1] - The SS16 project increased output from 7,000 tons to 8,000 tons, with labor productivity rising from 2.75 million to 4.4 million yuan per employee, while SY25 is expected to achieve a labor productivity of 4.32 million yuan per employee [1] Group 2: Smart Warehouse and Production Automation - In 2025, the company completed the construction of an intelligent warehouse with a total area of 15,562.70 m² and over 23,000 storage locations, capable of storing approximately 300,000 items [2] - The intelligent warehouse features automated functions such as inbound and outbound logistics, and integrates with WMS, ERP, TMS, and AGV systems for efficient management and space utilization [2] - LuKang Pharmaceutical implemented six automation enhancement projects in its production lines, including advanced equipment like AGV transporters and high-speed capping machines, which improved overall equipment levels and reduced labor intensity [2] Group 3: Smart Management Platform and Future Goals - The company has developed a smart operational management platform centered around ERP, integrating various management systems to streamline financial, sales, procurement, and production processes [3] - By 2025, LuKang Pharmaceutical plans to fully implement quality management system modules and expand RPA applications to 35 scenarios, enhancing operational efficiency and decision-making capabilities [3] - During the 14th Five-Year Plan period, the company will promote AI-driven business innovations and accelerate its digital transformation to ensure industry-leading standards in smart construction and high-quality development [3]

Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 63.26% to 72.13% compared to the previous year, primarily due to non-recurring gains and market pressures [2][4]. Group 1: Performance Forecast - The performance forecast applies to a scenario where the company achieves profitability but experiences a net profit decline of over 50% compared to the same period last year [2]. - For the fiscal year 2025, the company expects a net profit attributable to shareholders of the parent company to be between 110 million and 145 million yuan, representing a year-on-year decrease of 24.962 million to 28.462 million yuan [4]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 80 million and 118 million yuan, reflecting a year-on-year decrease of 9.058 million to 12.858 million yuan [4]. Group 2: Previous Year’s Performance and Financial Status - In the previous year, the total profit was 433.9014 million yuan, with a net profit attributable to shareholders of the parent company at 394.6157 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 208.5835 million yuan, with earnings per share at 0.44 yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is primarily attributed to the impact of non-recurring gains from the previous year, where significant asset disposal gains were realized due to the completion of land transfer procedures [6]. - Market factors such as reduced product demand, intense industry competition, and price reductions from national procurement policies have pressured overall industry profits, leading to a decline in revenue and gross profit for the company [6]. - Strategic investments in high-quality development and increased R&D expenditures for innovative drugs and high-end formulations have also contributed to short-term cost pressures affecting profits [6].

Core Viewpoint - Lu Kang Pharmaceutical (600789) expects a significant decrease in net profit for 2025, projecting a range of 110 million to 145 million yuan, representing a year-on-year decline of 63.26% to 72.13% [1] Financial Performance - The anticipated decrease in profit is primarily attributed to the impact of non-recurring gains and losses, market factors, and short-term cost pressures related to strategic investments [1] - The previous year's performance was boosted by substantial asset disposal gains from the completion of land transfer procedures, leading to significant fluctuations in this year's results [1] Industry Context - The pharmaceutical industry is facing overall profit pressure due to slowing product market demand, intense competition, and price reductions from national centralized procurement policies [1] - Traditional human formulation products are experiencing significant changes in terminal demand, leading to pressures on volume and pricing adjustments, which have negatively impacted revenue and gross profit [1] Strategic Investments - To promote high-quality development, the company is increasing its investment in research and development, focusing on innovative drugs, high-end formulations, and synthetic biology [1] - The increase in amortization expenses related to previously approved technical assets and the sustained high level of R&D investment are expected to have a short-term negative impact on profits [1]

Core Viewpoint - The company, LuKang Pharmaceutical, anticipates a significant decline in net profit for the year 2025, projecting a decrease of 24.96 million to 28.46 million yuan compared to the previous year, which translates to a year-on-year reduction of 63.26% to 72.13% [1] Financial Performance - The expected net profit for 2025 is estimated to be between 110 million yuan and 145 million yuan [1] - This represents a substantial decrease from the previous year's figures, indicating potential challenges in the company's financial performance [1]

Core Viewpoint - LuKang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan, representing a decrease of approximately 249.62 million to 284.62 million yuan compared to the previous year, which translates to a year-on-year decline of 63.26% to 72.13% [1] Financial Summary - The projected net profit for 2025 is estimated to be between 110 million to 145 million yuan [1] - The expected decrease in net profit compared to the previous year is between 249.62 million to 284.62 million yuan [1] - The year-on-year percentage decline in net profit is forecasted to be between 63.26% and 72.13% [1]

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]

Financial Projections - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 110 million and 145 million yuan, representing a year-on-year decrease of 63.26% to 72.13%[2] - The net profit excluding non-recurring gains and losses is projected to be between 80 million and 118 million yuan, reflecting a year-on-year decline of 43.43% to 61.65%[3] - The previous year's net profit attributable to shareholders was 394.62 million yuan, with a total profit of 433.90 million yuan[4] Performance Factors - The decrease in performance is primarily due to non-recurring gains from land transfer in the previous year, market demand slowdown, and increased competition[5] R&D Investment - The company is increasing investment in R&D for innovative drugs and high-end formulations, which is expected to impact short-term profits[5]